Who Paid My Doc
Osilodrostat
Drug Endocrine Agent
General payments
$158,129
Research payments
$835,330
Through program year 2025, $158,129 in general payments and $835,330 in research payments were reported against Osilodrostat (Endocrine Agent).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $84,645 | 55 |
| 2025 | Research | $628,893 | 213 |
| 2024 | General | $73,483 | 38 |
| 2024 | Research | $206,437 | 475 |
Breakdown
The top 5 of 13 recipients; each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 10 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
93 general · 688 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.